Cigarette smoking is well recognised as a major cause of chronic airflow limitation.'2 The effect of cigarette smoking and the development of chronic airflow limitation are usually assessed by change in forced expiratory volume in one second (FEVy) in Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers population of about 6000 adults, all of whom were asked to take part in a population study every three years from 1966 to 1981. In 1981, 3940 attenders completed a questionnaire and had lung function measured and it is this group of subjects for ,vhom we have obtained retrospective dataAh 1984 data were collected from a restricted sample of 484 subjects only. All subjects completed a self administered questionnaire and had FEVy and FVC measured at each attendance.
The questions, taken from the Medical Research Council questionnaire,22 related to respiratory and smoking history. Those considered to have a history of asthma were excluded from analysis. These were individuals who had ever answered "yes" to the question "Have you ever been diagnosed as having bronchial asthma?" or who answered "yes" in three or more of the studies to either of the questions "Have you ever had wheezing or tightness in the chest?" or "Have you ever had shortness of breath coming on while you are resting?" Five hundred and eight subjects (340o of the non-asthmatic group) stopped smoking before or during the study and were classified as ex-smokers. These ex-smokers, together with pipe and cigar smokers, were also excluded from the analyses.
Non-smokers were defined as subjects who had never smoked regularly (one or more cigarettes a day) either before or during the study. Smokers Stepwise multiple regression with FEVy slope as the dependent variable was used to calculate the effects of age (in the final study), sex, and smoking on decline of FEVI. Although the distribution of slopes for non-smokers was skewed (fig 1) , examination of the standardised residuals showed only five values outside the normal distribution. Data analyses excluding these outliers showed that they did not influence the findings and analyses of the full data set are therefore presented.
Results
There were 759 non-smokers and 225 smokers who were non-asthmatic and who had sufficient data available for analysis. Of these subjects, 1000 had data from seven studies, 610,, from six studies, and 290o from four or five studies. Table 1 shows the percentage distribution of the sample by smoking history, sex, and age at the time of the final study. There were more female than male non-smokers but approxi- Decline of lung function and development of chronic airflow limitation: a longitudinal study of non-smokers and smokers Table 3 shows the prevalence of chronic airflow limitation and respiratory symptoms in non-smokers and smokers. There was significantly more chronic airflow limitation in the smokers (men 23-6%, women 17-8%) than in the non-smokers (men 5-2%, women 7-6%) (p < 0 001). The prevalence of respiratory symptoms was also higher in smokers (p < 0-001). In subjects with chronic airflow limitation the proportion of non-smokers and smokers who reported respiratory symptoms appeared similar, though the results are influenced by small numbers of subjects with chronic airflow limitation in the lower age groups. Non-smokers with chronic airflow limitation were on average older than smokers: 570 were 70 years or older at the time of the final study compared with 210% of smokers (p < 0-001).
Discussion
This study provides further documentation of the decline in lung function in adult life in smokers and non-smokers, and quantifies the role of cigarette smoking in reducing lung function and causing chronic airflow limitation and disability. We found that the rate of decline of lung function in smokers, as a group, was more rapid than that of non-smokers and was related to the amount smoked. Thus, in general, a smoker may expect to have lower lung function than a non-smoker of the same height and age and a more rapid decline in lung function.
This longitudinal study includes data for a large number of subjects seen at regular intervals over 9-18 years Values for decline in FEV, in both nonsmokers and smokers in this study are similar to values from other studies for subjects aged less than 60 years. Although decline in FEV, had a significant association with age and number of cigarettes smoked, 90% of the variation in FEV, slope remains unexplained. The finding that height, age, and smoking history account for only 10% of the variation is consistent with the results of other studies.6 1424 We found that, when FEV, was adjusted for Although our study was not designed to assess the prevalence of respiratory illness accurately, we found a higher prevalence of chronic airflow limitation than previous studies, especially in non-smokers and in women. Among the men 240/ of the regular smokers had chronic airflow limitation. Previous estimates suggest that only 10-20% of men who are heavy smokers develop chronic airflow limitation,' "' though exclusion of subjects aged 60 or 70 years may in part explain this lower prevalence. Chronic airflow limitation is reported to occur more commonly in men than in women,'7 but its occurrence in women has rarely been investigated. The prevalence of the condition in women smokers in our study was 18%, almost as high as in men. We also found that 7% of non-asthmatic non-smokers had chronic airflow limitation, compared with a prevalence of 4% in a study by Krzyzanowski et al."
Although asthma and smoking remain the most important identified causes of chronic airflow limitation"'829 apparently the condition may develop in the absence of these factors and to a similar extent in women. Its causes, particularly in non-smokers, require further investigation.
Most subjects with chronic airflow limitation (62% of non-smokers and 54% of smokers) did not report shortness of breath or persistent cough with phlegm. Thus symptoms may not occur, and the disease may go unrecognised until severe and irreversible loss of FEV, has taken place. Dyspnoea has been shown to occur when the FEV, has fallen to below 1-5 or 2-0 litres' so that, in smokers with an FEV1 decline of 80-100 ml a year, 20 years may elapse before the reduction in FEVy is sufficient to cause shortness of breath. This study presents data to confirm that lung function in smokers, as a group, declines more rapidly than that of non-smokers. The effects of cigarette smoking, as a modifiable factor, have been extensively investigated and improvement in lung function has been shown to follow a decrease in smoking.'0 13 24 Further studies are required to determine the point at which a steep rate of decline can be tempered and to determine the characteristics that indicate that the course of the disease is largely irreversible.
This study has shown that steep rates of decline are not limited to men or to smokers, and not necessarily associated with respiratory symptoms, though chronic airflow limitation may be expected to result in disability eventually. In this context relatively little attention has been given to factors other than smoking, such as childhood events,31 32 physiological characteristics,5 17 3335 or environmental and social conditions,'7 which are known to affect lung function and which may play a part in the development of chronic airflow limitation. In particular, bronchial hyperresponsiveness is associated with chronic airflow limitation"2 and reduced lung function36 and its role deserves further investigation. Because the condition is a common cause of disability and a risk factor for other serious illness,37 and because it has been impossible to prevent smoking in whole populations or alter the course of the disease by other means, identification of those at high risk remains an essential health care issue.
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